Trial Profile
A Single Arm Exploratory Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Locally Advanced Esophageal Squamous Cell Carcinomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jul 2021
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- 01 Jul 2021 Results published in the Oncologist
- 02 Dec 2019 Status changed from recruiting to completed.
- 21 Jul 2017 New trial record